News
IMNN
1.640
+17.14%
0.240
IMNN Stock Earnings: Imunon Beats EPS for Q4 2023
Imunon reported earnings per share of -52 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Imunon's results were above the analyst estimate of -$2.30 per share. The company just reported results for fourth quarter.
Investorplace · 20h ago
Imunon Inc reports results for the quarter ended in December - Earnings Summary
Imunon Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 52 cents per share. The mean expectation of two analysts was for a loss of 41 cents. Imunon shares had risen by 105.9% this quarter.
Reuters · 1d ago
Imunon Q4 EPS $(0.52) Beats $(2.30) Estimate
Benzinga · 1d ago
Imunon FY2023 EPS $(2.16) Beats $(2.30) Estimate
Benzinga · 1d ago
Imunon GAAP EPS of -$2.16 beats by $0.07
Imunon, Inc. FY GAAP EPS of -$2.16 beats by $0.07. The Company ended 2023 with $15.7 million in cash, investments and accrued interest receivable. The company believes it has sufficient capital resources to fund its operations into 2024.
Seeking Alpha · 1d ago
*Imunon Believes It Has Sufficient Cap Resources to Fund Its Ops Into the 4Q of 2024 >IMNN
Dow Jones · 1d ago
*Imunon Ended 2023 With $15.7M in Cash, Investments and Accrued Interest Receivable >IMNN
Dow Jones · 1d ago
*Imunon FY23 Loss/Shr $2.16 >IMNN
Dow Jones · 1d ago
Earnings Scheduled For March 28, 2024
Universal Stainless is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Walgreens Boots Alliance is likely to report earnings for its fourth quarter. Companies Reporting Before The Bell include Shimmick and Universal Stainless. Companies reporting after the bell include INmune Bio and Oxford Industries.
Benzinga · 1d ago
Pre-Market Earnings Report for March 28, 2024 : AFMD, ATAT, AWH, AZUL, CNF, DLNG, DOOO, DRIO, GROY, HUT, IMNN, ITRM
NASDAQ · 1d ago
Preview: Imunon's Earnings
Imunon is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Analysts estimate the company will report an earnings per share of $-0.57. Last quarter the company beat EPS by $0.29. Shares of Imunon were trading at $1.15 as of March 26.
Benzinga · 1d ago
Imunon FY Earnings Preview
Imunon, Inc. Is scheduled to announce FY earnings results on Thursday, March 28th. The consensus EPS Estimate is -$2.23 for the quarter. Over the last 1 year, IMNN has beaten EPS estimates 50% of the time and has beaten revenue estimates.
Seeking Alpha · 1d ago
Notable earnings before Thursday's open
Seeking Alpha · 2d ago
Imunon Inc <IMNN.OQ> expected to post a loss of 41 cents a share - Earnings Preview
Imunon Inc expected to post a loss of 41 cents a share - Earnings Preview. The company is expected to show a fall in quarterly revenue when it reports results on March 28 for the period ending December 31 2023 LSEG's mean analyst estimate for Imunon is for a loss of 41 cents per share.
Reuters · 3d ago
Weekly Report: what happened at IMNN last week (0318-0322)?
Weekly Report · 4d ago
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
IMUNON, Inc. Is a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines. The Company will host a conference call on March 28, 2024 to discuss financial results for the year ended December 31, 2023. IMNN-001 is in Phase 2 clinical development for the treatment of ovarian cancer.
Barchart · 03/21 16:00
Weekly Report: what happened at IMNN last week (0311-0315)?
Weekly Report · 03/18 11:04
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN) and CalciMedica (CALC)
TipRanks · 03/13 16:30
IMUNON Files IND Application To Begin Human Testing Of IMNN-101; Expects Enrollment In Phase 1 Proof-Of-Concept Study Of DNA-Based Vaccine Technology To Begin In Q2
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2. Company expects to begin study in the second quarter of 2024. IMNN-101 is a non-viral DNA-mediated immunotherapy and next-generation vaccine technology.
Benzinga · 03/13 12:07
Imunon Announces CEO Resignation and Interim Leadership Transition
TipRanks · 03/12 21:23
More
Webull provides a variety of real-time IMNN stock news. You can receive the latest news about Imunon Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. It is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. It has two platform technologies: TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 works by instructing the body to produce cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, it is conducting preclinical studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus to validate its PLACCINE platform. Its platform technologies are based on the delivery of nucleic acids with synthetic delivery systems that are independent of viral vectors or devices.